Modified B cells and methods of use thereof

US12037604B2 · kind B2 · utility

Assignee

• Walking Fish Therapeutics, Inc. · US

Inventors

• Kathleen Boyle · South San Francisco, US
• Hangil Park · San Francisco, US
• Srinivas Kothakota · Pacifica, US
• Mark J. Selby · San Francisco, US
• Thomas Brennan · Nyack, US
• Lewis T. Williams · San Francisco, US

Key dates

• Filing date: May 11, 2023
• Grant date: Jul 16, 2024
• Expiry date: May 11, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.